These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20640910)

  • 1. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors.
    Pedersen SJ; Hetland ML; Sørensen IJ; Ostergaard M; Nielsen HJ; Johansen JS
    Clin Rheumatol; 2010 Nov; 29(11):1301-9. PubMed ID: 20640910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and circulating biomarkers of inflammation, angiogenesis, and cartilage and bone turnover.
    Pedersen SJ; Sørensen IJ; Lambert RG; Hermann KG; Garnero P; Johansen JS; Madsen OR; Hansen A; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen KH; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Østergaard M
    Arthritis Rheum; 2011 Dec; 63(12):3789-800. PubMed ID: 22127697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNFα inhibitors.
    Pedersen SJ; Sørensen IJ; Garnero P; Johansen JS; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Lambert R; Hansen A; Østergaard M
    Ann Rheum Dis; 2011 Aug; 70(8):1375-81. PubMed ID: 21551511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma YKL-40: a potential biomarker for psoriatic arthritis?
    Jensen P; Wiell C; Milting K; Poggenborg RP; Østergaard M; Johansen JS; Skov L
    J Eur Acad Dermatol Venereol; 2013 Jul; 27(7):815-9. PubMed ID: 22621388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNFalpha antagonist therapy.
    Wendling D; Cedoz JP; Racadot E
    Joint Bone Spine; 2008 Oct; 75(5):559-62. PubMed ID: 18674944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum markers in early-stage and locally advanced melanoma.
    Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P
    Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects.
    Nielsen AR; Plomgaard P; Krabbe KS; Johansen JS; Pedersen BK
    Cytokine; 2011 Jul; 55(1):152-5. PubMed ID: 21478032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma IL-6, plasma VEGF, and serum YKL-40: relationship with disease activity and radiographic progression in rheumatoid arthritis patients treated with infliximab and methotrexate.
    Knudsen LS; Ostergaard M; Baslund B; Narvestad E; Petersen J; Nielsen HJ; Ejbjerg BJ; Szkudlarek M; Johansen JS
    Scand J Rheumatol; 2006; 35(6):489-91. PubMed ID: 17343261
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.
    Appel H; Janssen L; Listing J; Heydrich R; Rudwaleit M; Sieper J
    Arthritis Res Ther; 2008; 10(5):R125. PubMed ID: 18945353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials.
    Brahe CH; Dehlendorff C; Østergaard M; Johansen JS; Ørnbjerg LM; Hørslev-Petersen K; Stengaard-Pedersen K; Junker P; Ellingsen T; Lindegaard H; Hansen I; Lottenburger T; Jacobsen S; Jurik AG; Hetland ML
    Scand J Rheumatol; 2018 Jul; 47(4):259-269. PubMed ID: 29336711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome.
    Knudsen LS; Klarlund M; Skjødt H; Jensen T; Ostergaard M; Jensen KE; Hansen MS; Hetland ML; Nielsen HJ; Johansen JS
    J Rheumatol; 2008 Jul; 35(7):1277-87. PubMed ID: 18597410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
    Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The VEGF and BMP-2 levels in patients with ankylosing spondylitis and the relationship to treatment with tumour necrosis factor alpha inhibitors.
    Tošovský M; Bradna P; Andrýs C; Andrýsová K; Cermáková E; Soukup T
    Acta Medica (Hradec Kralove); 2014; 57(2):56-61. PubMed ID: 25257151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased plasma YKL-40/chitinase-3-like-protein-1 is associated with endothelial dysfunction in obstructive sleep apnea.
    Jafari B; Elias JA; Mohsenin V
    PLoS One; 2014; 9(5):e98629. PubMed ID: 24878721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population.
    Andreassen M; Raymond I; Hildebrandt P; Kistorp C; Rathcke C; Vestergaard H; Faber J; Kristensen LO
    Inflamm Res; 2010 Jul; 59(7):503-10. PubMed ID: 20047081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality.
    Johansen JS; Pedersen AN; Schroll M; Jørgensen T; Pedersen BK; Bruunsgaard H
    Clin Exp Immunol; 2008 Feb; 151(2):260-6. PubMed ID: 18070151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
    Hottinger AF; Iwamoto FM; Karimi S; Riedel E; Dantis J; Park J; Panageas KS; Lassman AB; Abrey LE; Fleisher M; Holland EC; DeAngelis LM; Hormigo A
    Ann Neurol; 2011 Jul; 70(1):163-9. PubMed ID: 21391238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis.
    Turina MC; Yeremenko N; Paramarta JE; De Rycke L; Baeten D
    Arthritis Res Ther; 2014 Aug; 16(4):413. PubMed ID: 25135077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis.
    Romero-Sanchez C; Jaimes DA; Londoño J; De Avila J; Castellanos JE; Bello JM; Bautista W; Valle-Oñate R
    Clin Exp Rheumatol; 2011; 29(5):828-34. PubMed ID: 22041179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.